On March 20, 2026, the U.S. FDA approved nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adults and pediatric patients aged 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL). :contentReference[oaicite:14]{index=14}
On the same date, the FDA also granted traditional approval for nivolumab in adults with relapsed or refractory cHL for two indications that previously received accelerated approval (in 2016 and 2017, respectively). :contentReference[oaicite:15]{index=15}
Regulatory summary and eligible patient population
Indication, stage, and age
New approval (combination): nivolumab + AVD for adults and pediatric patients ≥12 years with previously untreated Stage III/IV cHL. :contentReference[oaicite:16]{index=16}
Traditional approval conversion in relapsed/refractory cHL (adults)
Converted to traditional approval (adults):
- After autologous HSCT and brentuximab vedotin
- After ≥3 lines of systemic therapy that includes autologous HSCT
These indications had previously received accelerated approval and were converted to traditional approval with this action. :contentReference[oaicite:17]{index=17}
Key trial (SWOG 1826 / NCT03907488): design and efficacy outcomes
Trial design and comparator (BV + AVD)
Efficacy of nivolumab + AVD was evaluated in Study CA209-8UT (SWOG 1826; NCT03907488), a randomized, open-label, multicenter trial in patients aged ≥12 years with previously untreated Stage III/IV cHL. A total of 994 patients were randomized 1:1 to receive either nivolumab + AVD or brentuximab vedotin (BV) + AVD for 6 cycles. :contentReference[oaicite:18]{index=18}
PFS (HR 0.42) and follow-up details
The primary endpoint was investigator-assessed progression-free survival (PFS). The trial demonstrated superiority of PFS for nivolumab + AVD, with a hazard ratio of 0.42 (95% CI 0.27–0.67; p<0.0001). :contentReference[oaicite:19]{index=19}
After a median follow-up of 13.7 months, median PFS was not reached in either arm. After a median follow-up of 36.7 months, deaths occurred in 1.8% of patients in the nivolumab + AVD arm and 3.4% in the BV + AVD arm. :contentReference[oaicite:20]{index=20}
Safety profile and clinical considerations
Serious adverse reactions and immune-mediated AEs
In the nivolumab + AVD arm, serious adverse reactions occurred in 39% of patients, and immune-mediated adverse reactions occurred in 9% (Grade 3–4: 2.7%). :contentReference[oaicite:21]{index=21}
Operationally, implementing standardized pathways for early recognition and management of immune-related toxicities—alongside chemotherapy supportive care—is critical for safe delivery.
Dosing (adult/pediatric) and primary G-CSF prophylaxis
Recommended nivolumab dosing is 240 mg (adults and pediatric patients ≥40 kg) or 3 mg/kg (pediatric patients <40 kg), administered IV with AVD on Days 1 and 15 of each 28-day cycle for up to 6 cycles. Primary G-CSF prophylaxis is recommended starting in Cycle 1. :contentReference[oaicite:22]{index=22}
Regulatory context (Project Orbis, Priority Review, Assessment Aid)
Project Orbis (concurrent international review)
This review was conducted under Project Orbis (FDA Oncology Center of Excellence). For this review, the FDA collaborated with Israel’s Ministry of Health, Australia’s TGA, Health Canada, and Switzerland’s Swissmedic (applications may still be under review in partner agencies). :contentReference[oaicite:23]{index=23}
Priority Review, Orphan Drug designation, Summary Review
The application was granted Priority Review and Orphan Drug designation. The FDA conducted a Summary Review and used the Assessment Aid to facilitate assessment. :contentReference[oaicite:24]{index=24}
Clinical positioning and outlook (frontline advanced cHL)
Versus BV + AVD: potential impact on frontline choices
Because the comparator was BV + AVD, SWOG 1826 directly informs real-world frontline decision-making. The PFS benefit (HR 0.42) suggests nivolumab + AVD may reshape standards for selected patients with previously untreated advanced cHL. :contentReference[oaicite:25]{index=25}
Implementation considerations: irAE management and supportive care
Key practical considerations include readiness for immune-related toxicity management, infection risk mitigation, and consistent supportive care (including primary G-CSF prophylaxis from Cycle 1). :contentReference[oaicite:26]{index=26}
Sources
- AACR FDA Approval Alert (2026-03-20): nivolumab + AVD in previously untreated Stage III/IV cHL
- Study CA209-8UT (SWOG 1826; NCT03907488)
- Opdivo (nivolumab) Prescribing Information: to be posted on Drugs@FDA
Comments